Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower women to take control of their health by providing quick, easy access ...

In this case, I was visiting my grandparents. And what I forgot was T-shirts. Yes, I forgot to pack an entire category of clothing. Not long after my arrival, I bought an emergency T-shirt from a ...

On World Contraception Day, Organon, a pharmaceutical company focused on women’s health, ignited discussions on women’s reproductive health and their right to choose at the recently held event ...